Healthcare Realty Trust Azioni (NYSE: HR)

Healthcare Realty Trust (NYSE:HR) Azioni

Healthcare Realty Trust

Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.

Real Estate

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Incertezza sui mercati? I dividendi nel settore immobiliare possono offrire stabilità e guadagni. Le azioni da monitorare.

Titoli a dividendi: 3 azioni immobiliari ad alto rendimento da tenere d&#39;occhio

Dividend Yield

Le valutazioni aggiornate degli analisti rivelano opportunità e rischi nel settore REIT: ecco tre titoli per un flusso di cassa costante.

3 titoli immobiliari ad alto rendimento sotto la lente degli esperti

Earnings

Come proteggere i tuoi investimenti in periodi di incertezza? Focus sui titoli del settore immobiliare che offrono rendite elevate.

3 titoli con dividendi oltre il 6% per un portafoglio anti-crisi

Healthcare Realty Trust Incorporated Common Stock

Healthcare Realty Trust Inc

HEAR ATLAST HOLDINGS INC by Hear AtLast Holdings, Inc.

Hear AtLast Holdings Inc

Hera SpA

H&R Block Inc

HARBOR BANKSHARES CORP by Harbor Bankshares Corporation

Harbor Bankshares Corp

HARBOR DIVERSIFIED INC by Harbor Diversified, Inc.

Harbor Diversified Inc

HERSHEY CREAMERY CO by Hershey Creamery Co.

Hershey Creamery Co

Hurricane Energy PLC

Here Media Inc

Stans Energy Corp

Harfang Exploration Inc

HERITAGE NOLA BANCORP INC by Heritage Nola Bancorp Inc

Heritage NOLA Bancorp Inc

Hargreaves Lansdown PLC

Hargreaves Lansdown PLC ADR

HARVARD APPRATS REG TCH by Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc

Herc Holdings Inc

Horiba Ltd

HKR INTL LTD ORD by HKR International Ltd.

HKR International Ltd

REVOLUTION CO LTD by REVOLUTION CO LTD.

Hormel Foods Corp

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Holdings Inc

Hydro One Ltd

HRnetGroup Ltd

HIROSE ELECTRIC UNSP/ADR by Hirose Electric

Hirose Electric Co Ltd

HIROGIN HOLDINGS INC by Hirogin Holdings Inc.

Hirogin Holdings Inc

Harrow Inc

Harrow, Inc. - 8.625% senior notes due 2026

Harrow, Inc. - 11.875% Senior Notes due 2027

HAIER SMART HOME CO LTD by HAIER SMART HOME CO LTD.

Haier Smart Home Co Ltd

HORRISON RESOURCES INC by Horrison Resources Inc.

Horrison Resources Inc

HARVEST OIL & GAS CORP by Harvest Oil & Gas Corp.

Harvest Oil & Gas Corp

HIRERIGHT HLDGS CORP COM

Heritage Insurance Holdings, Inc. Common Stock

Heritage Insurance Holdings Inc

Tema GLP-1, Obesity & Cardiometabolic ETF

Heart Tronics Inc

Heron Therapeutics Inc

H&R Real Estate Investment Trust Stapled Units Cons of 1 H&R REIT Ut ' 1 H&R Finance Trust Ut

H&R Real Estate Investment Trust

Harvia PLC

HORIZON CONST DEV LTD by HORIZON CONSTRUCTION DEVELOPMENT LTD.

Horizon Construction Development Ltd

HORIZON MINERALS LTD by HORIZON MINERALS LTD.

Horizon Minerals Ltd

Horizon Technology Finance Corporation - Common Stock

Horizon Technology Finance Corp

HORIZON ROBOTICS B by HORIZON ROBOTICS

Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) ("Healthcare Realty" or the "Company") today announced that its Board of Directors ("Board") has unanimously appointed Peter A. Scott to be the Company's President and Chief Executive Officer following an extensive and rigorous search process.&nbsp; He will be based at the Company's Nashville headquarters and assume his new role on April 15, 2025.&nbsp;Mr. Scott is expected to be added to the Board following the Company's 2025 annual meeting of stockholders.
Since 2017, Mr. Scott served as Chief Financial Officer of Healthpeak Properties, Inc., an S&amp;P 500 company with approximately $25 billion of assets that primarily owns and develops healthcare real estate for outpatient medical and life science tenants.&nbsp; Before joining Healthpeak, he was a Managing Director in the Real Estate Investment Banking Group at Barclays.&nbsp;
Connie Moore, who has served as Interim President and CEO of the Company since November 2024, will transition out of that role and continue to serve on the Board.&nbsp;&nbsp;&nbsp;&nbsp;

Management

Healthcare Realty Names Healthpeak CFO Peter Scott as New CEO, Succeeding Interim Chief Connie Moore

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.40%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and slashed the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest HR news</a>.</li>
</ul>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.15%</li>
<li>Wells Fargo analyst Connor Siversky downgraded the stock from Overweight to Equal-Weight and lowered the price target from $41 to $39 on March 27, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and increased the price target from $38 to $39 on March 18, 2025. This analyst has an accuracy rate of 70%</li>
<li>Recent News: On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">OHI news</a></li>
</ul>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 7.32%</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and increased the price target from $17.51 to $18.54 on Dec. 18, 2024. This analyst has an accuracy rate of 75%.</li>
<li>TD Cowen analyst Lance Vitanza initiated coverage on the stock with a Hold rating and a price target of $16.48 on July 16, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Feb. 25, Outfront Media reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest OUT news</a> </li>
</ul>
<figure class="wp-block-embed"> 
<div class="wp-block-embed__wrapper">
<a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock" title="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock</a>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 7% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 10.33%</li>
<li>RBC Capital analyst Michael Carroll maintained an Underperform rating and cut the price target from $12 to $11 on March 10, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and lowered the price target from $14 to $13 on Dec. 6, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 25, Easterly Government Props posted fourth-quarter FFO of 29 cents, in-line with estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DEA <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png" alt="" class="wp-image-824364" style="width:475px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-768x710.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 9.17%</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $15 to $13 on Feb. 3, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Wolfe Research analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Feb. 19, Park Hotels &amp; Resorts posted better-than-expected quarterly revenue.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">latest PK news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png" alt="" class="wp-image-824366" style="width:492px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-768x714.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.60%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and raised the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png" alt="" class="wp-image-824369" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

Wells Fargo analyst John Kilichowski maintains Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) with a Underweight and lowers the price target from $17 to $16.

Wells Fargo Maintains Underweight on Healthcare Realty Trust, Lowers Price Target to $16

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.33%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">HR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="397" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png" alt="" class="wp-image-798244" style="width:517px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-768x340.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.27%</li>
<li>JMP Securities analyst Aaron Hecht reiterated a Market Perform rating on Feb. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png" alt="" class="wp-image-798252" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-768x682.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 6.75%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and increased the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Jan. 27, EPR Properties elected John Peter (JP) Suarez to its Board of Trustees.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">latest EPR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png" alt="" class="wp-image-798248" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-768x683.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 6% Dividend Yields

Scotiabank analyst Nicholas Yulico maintains Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) with a Sector Perform and lowers the price target from $18 to $17.

Scotiabank Maintains Sector Perform on Healthcare Realty Trust, Lowers Price Target to $17

GuidanceThe Company's 2025 per share estimated guidance ranges are as follows:&nbsp;ACTUAL&nbsp;2025 GUIDANCE&nbsp;&nbsp;2024&nbsp;&nbsp;LOWHIGHEarnings per share$(1.81)&nbsp;$(0.28)$(0.20)NAREIT FFO per
Guidance
<ul>
<li>The Company's 2025 per share estimated guidance ranges are as follows:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td colspan="3">ACTUAL</td>
<td>&nbsp;</td>
<td colspan="6">2025 GUIDANCE</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>2024</td>
<td>&nbsp;</td>
<td colspan="4">&nbsp;LOW</td>
<td colspan="3">HIGH</td>
</tr>
<tr>
<td>Earnings per share</td>
<td>$</td>
<td>(1.81</td>
<td>)</td>
<td>&nbsp;</td>
<td>$</td>
<td>(0.28</td>
<td>)</td>
<td>$</td>
<td>(0.20</td>
<td>)</td>
</tr>
<tr>
<td>NAREIT FFO per share</td>
<td>$</td>
<td>0.52</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>$</td>
<td>1.44</td>
<td>&nbsp;</td>
<td>$</td>
<td>1.48</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Normalized FFO per share</td>
<td>$</td>
<td>1.56</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>$</td>
<td>1.56</td>
<td>&nbsp;</td>
<td>$</td>
<td>1.60</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
<ul>
<li>The Company's 2025 same store cash NOI growth estimated guidance range is 3.00% to 3.75%, which excludes the impact of Prospect Medical and Steward Health.</li>
</ul>

REIT

Guidance

Health Care

General

Healthcare Realty Expects 2025 EPS Loss Of $(0.28)-$(0.20) Versus $(1.81) In 2024, With Normalized FFO Of $1.56-$1.60 Versus $1.56 YoY

Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) reported quarterly earnings of $0.40 per share. This is a 2.56 percent increase over earnings of $0.39 per share from the same period last year. The company reported $309.77 million in sales this quarter. This is a 6.26 percent decrease over sales of $330.44 million the same period last year.

Healthcare Realty Trust Q4 2024 FFO $0.40 Up From $0.39 YoY, Sales $309.77M Down From $330.44M YoY

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Hedge Funds

KVUE

RIOT

Starboard Value's Latest 13F Filing Reveals New Stakes In Kenvue By 21.91M Shares, Pfizer By 15.37M Shares, Healthcare Realty Trust By 20.18M Shares, And Riot Platforms By 12.70M Shares.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.49%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Wells Fargo analyst James Feldman assumed coverage on the stock with an Underweight rating and raised the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: Healthcare Realty Trust will report results for the fourth quarter of 2024 on Wednesday, Feb. 19, before the market opens.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">HR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10092851/image-2-21.png" alt="" class="wp-image-774680" style="width:543px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10092851/image-2-21.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10092851/image-2-21-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10092851/image-2-21-768x720.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.17%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and raised the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On Jan. 27, EPR Properties elected John Peter (JP) Suarez to its Board of Trustees.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest EPR <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093027/image-80.png" alt="" class="wp-image-774683" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093027/image-80.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093027/image-80-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093027/image-80-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>)</h3>
<ul>
<li>Dividend Yield: 6.99%</li>
<li>JMP Securities analyst David Scharf initiated coverage on the stock with a Market Outperform rating and a price target of $115 on Jan. 27, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Scotiabank analyst Maher Yaghi maintained a Sector Perform rating and lowered the price target from $118 to $102 on Jan. 23, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Oct. 16, the company posted upbeat quarterly results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest CCI <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093057/image-2-22.png" alt="" class="wp-image-774686" style="width:409px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093057/image-2-22.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093057/image-2-22-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10093057/image-2-22-768x701.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields

Wedbush analyst Richard Anderson downgrades Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Neutral to Underperform and lowers the price target from $18 to $16.

Downgrades

Wedbush Downgrades Healthcare Realty Trust to Underperform, Lowers Price Target to $16

JP Morgan analyst Michael Mueller downgrades Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Overweight to Neutral and announces $19 price target.

JP Morgan Downgrades Healthcare Realty Trust to Neutral, Announces $19 Price Target

Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) today announced key leadership changes. Austen Helfrich, who has served as Interim Chief Financial Officer since October 1, 2024, has been formally appointed as the Company's permanent Executive Vice President and Chief Financial Officer, effective immediately. As part of a planned transition, Andrew Loope, Senior Vice President, Corporate Counsel and Secretary, will be promoted to Executive Vice President, General Counsel, and Secretary, succeeding John Bryant, effective January 1, 2025. Mr. Bryant will continue to serve as Executive Vice President and General Counsel through December 31, 2024, and will then remain with the Company in the role of Senior Vice President, Legal Affairs.
"Healthcare Realty is fortunate to have someone of Austen's talent and caliber ready to take on the role of permanent CFO. Since first joining Healthcare Realty in 2019, he has been instrumental in the formation and expansion of the Company's joint venture program, including partnerships with Nuveen, CBRE Investment Management and KKR. His significant financial acumen and industry experience will be invaluable to the Company as we continue to drive long-term shareholder value," said Constance "Connie" Moore, interim President and CEO.
Moore continued, "Andrew Loope has been a trusted advisor to the Company since joining our legal department from the Waller Lansden (now Holland &amp; Knight) law firm in 2008. John Bryant has dedicated more than 20 years of his professional career to Healthcare Realty. We are grateful for his many meaningful contributions as General Counsel and look forward to working closely with him and Andrew as they continue leading our legal team."
Ferguson Partners assisted the Board of Directors in the CFO search process.

Healthcare Realty Trust Named Interim CFO  Austen Helfrich As Permanent Finance Chief

Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) ("Healthcare Realty" or the "Company") today announced that its Board of Directors ("Board") has elected current director Tom Bohjalian as Independent Chair of the Board. It also announced that the Board has appointed three new independent directors with deep industry and leadership experience, David Henry, Glenn Rufrano and Don Wood, effective immediately, in connection with a cooperation agreement ("Agreement") with Starboard Value LP (together with its affiliates, "Starboard"). Mr. Henry and Mr. Rufrano have been appointed to the Company's existing board committee overseeing the previously announced president and CEO search, with Mr. Rufrano named Chair of the committee. The Company has also engaged Ferguson Partners to assist in the search process.

Healthcare Realty Trust Tapped Tom Bohjalian As Board Chair

Healthcare Realty Trust Names Constance Moore Interim CEO As Todd Meredith Steps Down

Healthcare Realty Trust Q3 Normalized FFO Per Share $0.39, Same As Prior Year, Sales $315.42M, Down From $342.26M Last Year

During the last three months, 5 analysts shared their evaluations of Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.2, a high estimate of $18.00, and a low estimate of $16.00. Surpassing the previous average price target of $16.20, the current average has increased by 6.17%.
<img src="https://www.benzinga.com/files/images/story/2024/1727809210_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Healthcare Realty Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Healthcare Realty Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Healthcare Realty Trust compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Healthcare Realty Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Healthcare Realty Trust's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Healthcare Realty Trust analyst ratings.</a>
<h2>All You Need to Know About Healthcare Realty Trust</h2>
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company considers merger and acquisition investment as a component of its operational growth strategy. It works with developers that have strong ties to a local health system and physicians. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
<h3>Healthcare Realty Trust: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Healthcare Realty Trust faced challenges, resulting in a decline of approximately -6.45% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Healthcare Realty Trust's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -45.97%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Healthcare Realty Trust's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Healthcare Realty Trust's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.21%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Healthcare Realty Trust's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 5 Takes On Healthcare Realty Trust

Healthcare Realty Trust Reaffirms Forward-looking Guidance And Expectations For 2024

Healthcare Realty Trust Rob Hull To Become COO; Austen Helfrich To Be Interim CFO

Press Releases

Healthcare Realty Trust Reports Results For the Third Quarter

Healthcare Realty Trust Announces CEO Transition

Healthcare Realty Trust Announces Changes to Board of Directors

Healthcare Realty Trust Announces Key Leadership Changes

Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call

Healthcare Realty Trust Reports Results for the Fourth Quarter and Announces Quarterly Dividend

Healthcare Realty Trust Announces Participation in Citi's 2025 Global Property CEO Conference and Provides Update on Rent Collection From Prospect Medical

Comments

Healthcare Realty Trust

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO